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Voriconazole versus itraconazole for antifungal prophylaxis
following allogeneic haematopoietic stem-cell transplantation
Invasive fungal infections (IFIs) are a major cause of morbidity
and mortality after allogeneic haematopoietic stem-cell trans-
plantation (alloHCT) (Ninin et al, 2001; Fukuda et al, 2003;
Garcia-Vidal et al, 2008). Invasive aspergillosis (IA) is the most
frequent IFI in this setting (1-year incidence of 11–14%)
(Fukuda et al, 2003; Garcia-Vidal et al, 2008), with major risk
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Summary
Antifungal prophylaxis for allogeneic haematopoietic stem-cell transplant
(alloHCT) recipients should prevent invasive mould and yeast infections
(IFIs) and be well tolerated. This prospective, randomized, open-label,
multicentre study compared the efﬁcacy and safety of voriconazole (234
patients) versus itraconazole (255 patients) in alloHCT recipients. The
primary composite endpoint, success of prophylaxis, incorporated ability to
tolerate study drug for ‡100 d (with £14 d interruption) with survival to day
180 without proven/probable IFI. Success of prophylaxis was signiﬁcantly
higher with voriconazole than itraconazole (48Æ7% vs. 33Æ2%, P<0Æ01);
more voriconazole patients tolerated prophylaxis for 100 d (53Æ6% vs. 39Æ0%,
P <0 Æ01; median total duration 96 vs. 68 d). The most common (>10%)
treatment-related adverse events were vomiting (16Æ6%), nausea (15Æ8%) and
diarrhoea (10Æ4%) for itraconazole, and hepatotoxicity/liver function
abnormality (12Æ9%) for voriconazole. More itraconazole patients received
other systemic antifungals (41Æ9% vs. 29Æ9%, P <0 Æ01). There was no
difference in incidence of proven/probable IFI (1Æ3% vs. 2Æ1%) or survival to
day 180 (81Æ9% vs. 80Æ9%) for voriconazole and itraconazole respectively.
Voriconazole was superior to itraconazole as antifungal prophylaxis after
alloHCT, based on differences in the primary composite endpoint.
Voriconazole could be given for signiﬁcantly longer durations, with less
need for other systemic antifungals.
Keywords: stem-cell transplant, azoles, invasive fungal disease, mould
infections, yeast infections.
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immunosuppressive drugs for GvHD and cytopenia (Garcia-
Vidal et al, 2008; Mikulska et al, 2009). Mortality from
invasive Aspergillus infections following alloHCT remains high
– between 67% and 87% (Lin et al, 2001; Kojima et al, 2004;
Mikulska et al, 2009) – though newer agents (including
voriconazole) may have improved survival (Upton et al,
2007; Neofytos et al, 2009).
Because IFIs are difﬁcult to diagnose and treat early, efforts
have turned to prevention. Effective broad-spectrum (covering
both moulds and yeasts) antifungal prophylaxis in alloHCT
patients may reduce IFI incidence, morbidity and mortality
(Bow et al, 2002; Fukuda et al, 2003). Oral azole antifungals
have the potential to be more convenient and cost-effective in
this setting. However, the optimal antifungal prophylaxis is
unknown, and there is a need to identify more effective, better-
tolerated agents. Fluconazole effectively prevents invasive
candidiasis during the post-engraftment period (Goodman
et al, 1992; Slavin et al, 1995), but does not have activity
against Aspergillus. Itraconazole, a broad-spectrum azole also
active against ﬁlamentous fungi, has shown efﬁcacy in this
setting (Glasmacher et al, 2003; Winston et al, 2003; Marr
et al, 2004; Vardakas et al, 2005; Simon et al, 2007). However,
the variable bioavailability of itraconazole tablets and poor
tolerability of itraconazole suspension may limit its use as a
prophylactic agent (Vardakas et al, 2005; Cornely et al, 2007;
Simon et al, 2007). The second-generation triazole posaco-
nazole also has anti-mould activity and was demonstrated to
be effective as primary prophylaxis for speciﬁc alloHCT
patients in a comparative trial with ﬂuconazole (Ullmann
et al, 2007). However, to date no mould-active agents have
been compared head-to-head in this setting.
Voriconazole is a second-generation, broad-spectrum triaz-
ole with in vitro and clinical activity against yeasts and moulds,
including Aspergillus, Candida, Fusarium and Scedosporium
species, but not zygomycetes (Cecil & Wenzel, 2009). Voric-
onazole has demonstrated safety and efﬁcacy as ﬁrst-line
treatment for invasive aspergillosis (Herbrecht et al, 2002) and
as ﬁrst-line treatment of serious Candida infections (Kullberg
et al, 2005), and can be given as a bioavailable oral (Cecil &
Wenzel, 2009) or an intravenous formulation. We evaluated
the efﬁcacy, safety and tolerability of voriconazole versus
itraconazole as antifungal prophylaxis in alloHCT recipients,
representing the ﬁrst head-to-head comparison of two mould-
active, orally available agents in this setting.
Patients and methods
Study design
This prospective, phase 3, randomized, open-label trial was
conducted from March 2006 to February 2009 in 47 transplant
centres across 12 countries, in compliance with the Declaration
of Helsinki, International Conference on Harmonization Good
Clinical Practice (GCP) guidelines and local regulatory
requirements. All participants gave written informed consent.
The protocol was approved by an institutional review board or
independent ethics committee at each study site.
Patients
Patients were aged ‡12 years and received sibling or unrelated
donor alloHCT for acute leukaemia, myelodysplasia, trans-
formed chronic myeloid leukaemia, or failed lymphoma
therapy. Patients with myeloablative and reduced-intensity
conditioning regimens were included. Patients with a proba-
ble/proven IFI during the 6 months prior to study entry, a
history of zygomycosis, impaired hepatic function, or use of
systemic antifungals within 7 d before study entry were
excluded. Patients who received concomitant medications
with major interactions with azoles were also not permitted to
enter the study. Detailed inclusion and exclusion criteria are
listed in the online data supplement (Data S1).
Stratiﬁcation and randomization
Patients were randomly assigned with equal probability to
either voriconazole (Vfend; Pﬁzer Inc, New York, NY, USA) or
itraconazole (Sporanox; Ortho-McNeil Janssen-Pharmaceuti-
cals Inc, Raritan, NJ, USA) using a permuted block random-
ization (block size 4) with stratiﬁcation by conditioning
regimen (myeloablative or reduced-intensity) and donor
relatedness (matched related or unrelated). Randomization
was also blocked by centre.
Prophylaxis was scheduled to start on the day of alloHCT, at
least 48 h after conditioning chemotherapy. The ﬁrst day of
study drug was considered as day 1. Following 1 d of
intravenous loading (6 mg/kg every 12 h), voriconazole was
administered as tablets or oral suspension at a dose of 200 mg
twice daily; the dose was halved for patients <40 kg. Following
2 d of intravenous loading doses (200 mg every 12 h),
itraconazole was given as oral solution at a dose of 200 mg
twice daily. Itraconazole capsules were permitted for up to
14 d if patients were temporarily unable to continue oral
solution. In case of mucositis or gut GvHD, patients could be
given either study drug intravenously (voriconazole: 4 mg/kg
twice daily; itraconazole: 200 mg once daily). Prophylaxis with
study drug was to be given for ‡100 d for all patients and
could be extended to day 180 if risk factors for IFI persisted
(Data S1). Regardless of study drug duration, all patients were
followed for 180 d for development of IFIs and 1 year for
survival.
Systemic antifungal therapy with a non-study agent could be
initiated for up to 14 d for persistent fever or signs of possible
IFI (Ascioglu et al, 2002) pending conﬁrmation of a proven/
probable IFI, at the discretion of the investigator, without the
patient being classiﬁed a prophylactic failure. Given that both
study drugs have activity against Aspergillus and because
testing was not universally available, a structured IFI screening
programme with galactomannan testing was not employed. An
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suspected and documented IFIs that occurred during the study
period and categorized them according to consensus criteria
current at study onset (Data S1) (Ascioglu et al, 2002).
Endpoints
In light of the fact that previous studies comparing different
agents as antifungal prophylaxis post-alloHCT were unable to
show any signiﬁcant differences in the overall incidence of IFI
or in patient survival, a composite endpoint was chosen for the
purposes of this trial. The primary endpoint, success of
prophylaxis, was deﬁned as the ability to tolerate study drug
for at least 100 d, with £14 d interruption, with survival
without proven/probable IFI to day 180. All patients who
discontinued study drug for more than 14 d in the 100-d
prophylaxis period, who died before or on day 180, or were
diagnosed with a proven/probable IFI before or on day 180
were regarded as treatment failures. Secondary analyses
included comparison of success of prophylaxis at day 100,
proven/probable IFI, use of systemic antifungal agents and
survival to day 180 and 1 year. Treatment satisfaction was
patient-assessed using a modiﬁed Treatment Satisfaction
Questionnaire for Medication (TSQM) and compared at day
14 (Atkinson et al, 2004, 2005). All analyses were conducted in
the modiﬁed intent-to-treat (mITT) population, which
included all randomized patients who had given informed
consent, received alloHCT and received at least one dose of
study medication. In addition, it was planned to assess plasma
levels of study drug on day 14 and at the time of breakthrough
IFI, using standard methods (Srivatsan et al, 2004; Andrews
et al, 2008); itraconazole plasma levels were also to be
evaluated after capsule use.
Safety assessment
Standard haematological and biochemical laboratory tests were
performed at screening and on days 0, 2, 14, 28, 56, 100, 140
and 180, while patients were receiving study drug. Electrocar-
diography was performed at screening and on days 2 and 28.
Adverse events and serious adverse events were reported until
14 and 28 d after last dose of study drug respectively. Adverse
event causality was assessed by investigators.
Statistical analysis
The primary analysis of the trial was intended to demonstrate
the non-inferiority of voriconazole to itraconazole in the
comparison of success of prophylaxis at day 180 in the mITT
population. Non-inferiority was inferred if the lower limit of
the two-sided 95% conﬁdence interval (CI) for the difference in
adjusted success rates (Data S1) at day 180 was ‡10%. If non-
inferiority was demonstrated, superiority would be inferred if
this two-sided 95% CI was positive. Assuming success rates of
50% for voriconazole and 45% for itraconazole, a sample size of
232 patients per group has 90% power to demonstrate non-
inferiority of voriconazole to itraconazole, and ‡80% power to
demonstrate superiority of voriconazole if the true success rates
for voriconazole and itraconazole were 57% and 44% respec-
tively. P values < 0Æ05 were considered signiﬁcant.
Patients randomized ( n = 503)
Assessed for eligibility (N = 534)
Excluded ( n = 31)
– Not meeting inclusion 
   criteria ( n = 14)
– Refused to participate ( n = 0)
– Other reasons ( n = 17)
Discontinued study ( n = 58) Discontinued study ( n = 80)
Allocated to itraconazole ( n = 260)
– Received allocated 
   intervention ( n = 255)
– Did not receive allocated 
   intervention ( n = 5)
Allocated to voriconazole ( n = 243)
– Received allocated 
   intervention ( n = 234)
– Did not receive allocated
   intervention ( n = 9)
Analysed ( n = 241)
– Excluded from safety and efficacy 
 analyses due to suspected breach 
 in GCP at 1 site ( n = 14)
Analysed ( n = 224)
– Excluded from safety and efficacy 
 analyses due to suspected breach 
 in GCP at 1 site ( n = 10)
Fig 1. Patient CONSORT ﬂow chart. GCP, Good Clinical Practice.
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Study population
A total of 534 patients were screened, 503 were randomized,
and 489 received at least one dose of study medication
(voriconazole n = 234, itraconazole n = 255; Fig 1). Detailed
reasons for the exclusion of screened patients from random-
ization, and why some randomized patients did not receive
study treatment, are listed in Data S1. Due to a suspected
breach in GCP, all patients from one study site (10 received
voriconazole, 14 received itraconazole) were excluded from all
analyses. Baseline characteristics, including conditioning reg-
imen and underlying haematological condition, were well
matched between the two arms (Table I). Treatment groups
were also balanced in the proportion of patients developing
GvHD (Data S1) and undergoing T-cell depletion.
Efﬁcacy
Success of antifungal prophylaxis at day 180, the primary
endpoint, was demonstrated in 48Æ7% of voriconazole and
33Æ2% of itraconazole patients, a difference of 16Æ4% (95%
CI, 7Æ7–25Æ1; P =0 Æ0002) after adjustment for randomization
strata. At day 100, the adjusted difference in success of
prophylaxis was 15Æ4% (95% CI, 6Æ6–24Æ2; P <0 Æ01),
favouring voriconazole (54Æ0% vs. 39Æ8% respectively). The
difference in success rates between treatments did not vary
across randomization strata (day 100, P =0 Æ29; day 180,
P =0 Æ41).
Table I. Patient baseline characteristics for the
modiﬁed intent-to-treat population.
* Voriconazole
(n = 224)
Itraconazole
(n = 241)
Randomization stratum, n (%)
Myeloablative and matched related 66 (29Æ5) 85 (35Æ3)
Myeloablative and mismatched/unrelated 59 (26Æ3) 58 (24Æ1)
Non-myeloablative and matched related 58 (25Æ9) 57 (23Æ7)
Non-myeloablative and mismatched/unrelated 41 (18Æ3) 41 (17Æ0)
Primary diagnosis, n (%)
Acute lymphocytic leukaemia 41 (18Æ3) 41 (17Æ0)
Acute myeloid leukaemia 98 (43Æ8) 109 (45Æ2)
Myelodysplastic syndrome 34 (15Æ2) 30 (12Æ4)
Failure of therapy for lymphoma 42 (18Æ8) 46 (19Æ1)
Transformation of chronic myeloid leukaemia 6 (2Æ7) 13 (5Æ4)
Other
  3( 1 Æ3) 2 (0Æ8)
Conditioning regimen, n (%)
 
Myeloablative 125 (55Æ8) 143 (59Æ3)
Non-myeloablative 99 (44Æ2) 98 (40Æ7)
Sex, n (%)
Male 130 (58Æ0) 146 (60Æ6)
Female 94 (42Æ0) 95 (39Æ4)
Age, years
Mean 43Æ34 2 Æ3
Range 11–70 13–70
Ethnicity, n (%)
White 207 (92Æ4) 219 (90Æ9)
Black 0 (0Æ0) 2 (0Æ8)
Asian 2 (0Æ9) 3 (1Æ2)
Other 15 (6Æ7) 17 (7Æ1)
Body mass index, kg/m
2
Mean 25Æ52 5 Æ8
Range 15Æ7–41Æ81 4 Æ9–49Æ5
*The modiﬁed intent-to-treat population included all patients who underwent haematopoietic
stem-cell transplant and received at least one dose of study drug. Patients from one study site
were excluded due to a suspected Good Clinical Practice breach.
 Primary diagnoses not permitted by the study protocol, i.e. myeloma (two voriconazole
patients)andchroniclymphocyticleukaemia(onevoriconazolepatient,twoitraconazolepatients).
 34Æ4% of voriconazole patients and 33Æ6% of itraconazole patients underwent in vivo T-cell
depletion, i.e. received antithymocyte immunoglobulin and/or alemtuzumab prior to screening
(P =0 Æ86).
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drug prophylaxis was 53Æ6% for voriconazole versus 39Æ0% for
itraconazole (95% CI of difference, 5Æ6–23Æ5; P <0 Æ01).
Median total durations of study drug treatment were 96 and
68 d respectively (P <0 Æ01). After the initial intravenous
dosing period, 112 (46Æ5%) itraconazole patients and 83
(37Æ1%) voriconazole patients received intravenous study drug
for at least 1 d (95% CI of difference, 0Æ5–18Æ3; P =0 Æ04).
Median durations of intravenous treatment were 10 and 11 d
respectively. Thirty-four (14Æ1%) itraconazole patients received
capsules for at least 1 d, with a mean duration of 11Æ7d .
Kaplan–Meier estimates of survival at day 100 (91Æ9% for
voriconazole, 92Æ3% for itraconazole) and day 180 (81Æ9% for
voriconazole, 80Æ9% for itraconazole) were similar. One-year
survival rates were 73Æ5% and 67Æ0% for voriconazole and
itraconazole respectively (P =0 Æ17; log-rank test). The hazard
ratio for death in the voriconazole group compared with the
itraconazole group was 0Æ79 (95% CI, 0Æ56–1Æ11). Kaplan–
Meier survival estimates from start of prophylaxis until day
365 by treatment are presented in Fig 2.
A total of three (1Æ3%) voriconazole patients developed a
proven or probable IFI during the study period, compared
with ﬁve (2Æ1%) itraconazole patients (95% CI for difference,
)3Æ1t o1 Æ6; P =0 Æ54; Table II). These IFIs occurred earlier
with itraconazole than voriconazole (average time to IFI: 73Æ8
vs. 118Æ0 d) and the only two treatment-emergent IFIs (deﬁned
as IFIs while receiving study drug or within 7 d of discontin-
uation) occurred in patients receiving itraconazole. There were
slightly more documented Aspergillus infections reported in
itraconazole patients (ﬁve vs. one respectively; P =0 Æ12), but
only one, in an itraconazole patient, was fatal. There were no
cases of zygomycosis reported in either study arm.
Treatment satisfaction
TSQM data were available for the majority of patients on day
14; the proportions of patients with these data were similar for
both treatments (Data S1). Based on these data, voriconazole
was superior to itraconazole in effectiveness (74Æ5 vs. 67Æ9;
P <0 Æ01), convenience (75Æ3 vs. 65Æ0; P <0 Æ01) and global
satisfaction (70Æ6 vs. 63Æ1; P <0 Æ01). Both study treatments
were similar in side-effect scores (91Æ7 vs. 88Æ4; P =0 Æ17). The
global satisfaction score at day 14 was a signiﬁcant predictor of
the ability to complete 100 d of prophylaxis (P =0 Æ02 on Cox
regression).
Plasma levels
Plasma drug levels at steady state were available in 116
voriconazole and 130 itraconazole patients (51Æ8% and 53Æ9%
respectively). However, only 34 voriconazole patients (15Æ2%)
had trough levels with a median concentration of 0Æ85 lg/ml
(range 0–4Æ53 lg/ml). Trough levels were >0Æ5 and >1 lg/ml
in 22 (64Æ7%) and 13 (38Æ2%) of these patients respectively. In
itraconazole patients, 24 patients (10Æ0%) had trough levels
with a median concentration of 0Æ89 lg/ml (range 0–2Æ46 lg/
ml). Trough levels were >0Æ5 and >1 lg/ml in 20 (83Æ3%) and
11 (45Æ8%) of these patients respectively.
Safety and tolerability
The most frequent all-causality adverse events in both
treatment arms were mucosal inﬂammation, diarrhoea,
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Fig 2. Kaplan–Meier survival estimates from start of prophylaxis until
day 365 for patients treated with voriconazole and itraconazole.
Table II. Invasive fungal infections during the study (diagnosed according to EORTC/MSG criteria; Ascioglu et al, 2002).
Level of diagnosis Pathogen
Body site
of IFI
Last dose of
study drug (d)
Onset of
IFI (d)
Voriconazole arm
Proven Candida krusei Blood 27 100
Proven Candida parapsilosis Blood 104 151
Probable Aspergillus fumigatus Lung 48 103
Itraconazole arm
Proven Aspergillus fumigatus Lung 19 82
Probable Aspergillus spp. Lung 9 11
Probable Aspergillus spp. Lung 21 20
Probable Aspergillus fumigatus Lung 14 80
Probable Aspergillus spp. Lung 20 176
EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; IFI, invasive fungal infection.
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all-causality adverse events occurred with voriconazole (47Æ8%
vs. 37Æ3%, P =0 Æ02), but the period of observation was
substantially longer.
Treatment-related gastrointestinal side effects (nausea, vom-
iting and diarrhoea) were more common with itraconazole
(P <0 Æ01 for each; Table III). Treatment-related hepatotoxic-
ity/liver function abnormalities occurred more frequently in
voriconazole patients (12Æ9% vs. 5Æ0%, P <0 Æ01), and ﬁve were
graded as severe, compared with one in the itraconazole arm
(P =0 Æ08). When adjusted for duration of observation, the
average number of treatment-related adverse events per 30 d of
treatment was 1Æ7 (95% CI, 1Æ1–2Æ2) for voriconazole and 2Æ0
(95% CI, 1Æ3–2Æ6) for itraconazole (P =0 Æ53). Of the ﬁve
voriconazole patients with severe hepatotoxicity, four survived
to the 1-year follow-up visit and none were considered by the
investigators to have died of study drug-related causes. Visual
impairment was also more frequent with voriconazole (5Æ4%
vs. 0Æ0%; P <0 Æ01), but all cases of visual impairment with
voriconazole were mild to moderate in severity, non-serious
and resolved without sequelae.
Randomized study treatment was discontinued prior to day
100 in 147 itraconazole compared with 104 voriconazole
patients (61Æ0% vs. 46Æ4%; P <0 Æ01). The most common
investigator-assessed reasons for itraconazole discontinuation
were adverse events (23Æ2%) and study drug intolerance
(21Æ6%). The most common reason for voriconazole discon-
tinuation was adverse events (29Æ9%; Data S1).
Use of other systemic antifungal agents
At least one systemic antifungal agent other than randomized
study drug was given during the study period in 101
itraconazole patients and 67 voriconazole patients (41Æ9% vs.
29Æ9%; P <0 Æ01). Forty-three (17Æ8%) itraconazole and 11
(4Æ9%) voriconazole patients received more than one such
agent (P <0 Æ01). More itraconazole patients received liposo-
mal amphotericin B and/or caspofungin (23Æ2% versus 15Æ2%,
P =0 Æ03), with respective median durations of 14 versus 10 d
(P =0 Æ19). Thirty-seven (15Æ4%) itraconazole patients received
voriconazole and/or posaconazole, and 10 (4Æ5%) voriconazole
patients received itraconazole or posaconazole (Table IV).
Discussion
This large, randomized trial represents the ﬁrst direct,
prospective comparison of two mould-active, orally available
agents as antifungal prophylaxis after alloHCT. Based on its
superiority in the composite primary endpoint incorporating
tolerability, IFI prevention and survival, voriconazole was
shown to be more effective than itraconazole for antifungal
prophylaxis in this setting. The main driver for this difference
was that signiﬁcantly more voriconazole patients were able to
tolerate at least 100 d of study drug with minimal interruption.
In this study we compared voriconazole with itraconazole,
another mould-active antifungal agent. Due to the high risk for
IA in this population (Fukuda et al, 2003; Garcia-Vidal et al,
2008), it was important to implement a study comparing two
mould-active agents for appropriate antifungal prophylaxis,
given that such an evaluation had not been prospectively
conducted to date. Because both agents have the potential to
prevent IFI, including Aspergillus infections, the ability to
tolerate study drug for relatively long durations becomes an
important consideration. In fact, current transplant regimens
are associated with prolonged periods of immunosuppression,
Table III. Most common treatment-related adverse events (‡5% in
either group) among modiﬁed intent-to-treat patients.
Adverse event
Voriconazole
(n = 224)
n (%)
Itraconazole
(n = 241)
n (%) P value
Vomiting 8 (3Æ6) 40 (16Æ6) <0Æ01
Nausea 16 (7Æ1) 38 (15Æ8) <0Æ01
Diarrhoea 9 (4Æ0) 25 (10Æ4) <0Æ01
Hepatotoxicity/liver
function test
abnormality
29 (12Æ9) 12 (5Æ0) <0Æ01
Headache 10 (4Æ5) 12 (5Æ0) 0Æ79
Visual impairment 12 (5Æ4) 0 (0) <0Æ01
Table IV. Other systemic antifungal agents given during the study
period.
*
Systemic antifungal
agent
Voriconazole
(n = 224)
n (%)
Itraconazole
(n = 241)
n (%) P value
Any systemic
antifungal agent
67 (29Æ9) 101 (41Æ9) <0Æ01
Caspofungin 24 (10Æ7) 48 (19Æ9) <0Æ01
Liposomal
amphotericin B
14 (6Æ3) 17 (7Æ1) 0Æ73
Caspofungin and/or
liposomal
amphotericin B
34 (15Æ2) 56 (23Æ2) 0Æ03
Amphotericin B
  4( 1 Æ8) 7 (2Æ9) 0Æ43
Fluconazole 21 (9Æ4) 37 (15Æ4) 0Æ051
Itraconazole
  5( 2 Æ2) 8 (3Æ3) 0Æ48
Voriconazole
  9( 4 Æ0) 34 (14Æ1) <0Æ01
Posaconazole
  5( 2 Æ2) 11 (4Æ6) 0Æ17
*Substantial numbers of patients received more than one such agent:
43 (17Æ8%) itraconazole and 11 (4Æ9%) voriconazole patients.
 In addition, 31 patients (30 from one site) received aerosolized
amphotericin B during the study: 16 voriconazole patients and 15
itraconazole patients.
 Ten voriconazole patients (4Æ5%) received itraconazole or posaco-
nazole. 37 itraconazole patients (15Æ4%) received voriconazole and/or
posaconazole. Some patients who discontinued study therapy subse-
quently recommenced the agent they were originally randomized to;
this was recorded as other licensed antifungal therapy.
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after alloHCT (Garcia-Vidal et al, 2008). In this study,
voriconazole was better tolerated than itraconazole for longer
durations. The major treatment-limiting side effects of itrac-
onazole were related to gastrointestinal intolerance, including
nausea, vomiting and diarrhoea.
Despite the higher incidence of treatment-related hepatic
and visual adverse events reported with voriconazole, patients
were able to continue voriconazole for longer periods than
itraconazole. The overall safety proﬁle for voriconazole in this
study was consistent with previous reports in similar patient
populations (Herbrecht et al, 2002; Queiroz-Telles et al, 2007;
Cecil & Wenzel, 2009). For example, a recently published
noncomparative study of voriconazole as secondary prophy-
laxis in allograft recipients reported hepatotoxicity in 4/45
(9%) patients; treatment duration was similar to that in our
trial (Cordonnier et al, 2010). The higher rates of hepatotox-
icity seen in the voriconazole arm (13% vs. 5%) need to be
considered in the context of the patient population. The
majority of allograft patients experience disturbances in
hepatic function, which are commonly multifactorial in origin
(e.g. due to GvHD or concomitant medications); this makes it
difﬁcult to attribute abnormal liver function tests speciﬁcally
to one drug or medical condition. Notably, signiﬁcant
derangement of hepatic function during the early post-
transplant phase can be an issue that requires adjustment of
prescribed drugs, including calcineurin inhibitors. Of the ﬁve
voriconazole patients (compared with one itraconazole
patient) with severe hepatotoxicity, four survived to the 1-
year follow-up visit, suggesting that these liver function test
abnormalities were generally reversible.
The better tolerability of voriconazole compared with
itraconazole was reﬂected in the TSQM results: patients
receiving voriconazole reported higher convenience and global
satisfaction scores at 2 weeks after start of study treatment. The
latter score correlated with the ability of voriconazole patients
to complete at least 100 d of study drug prophylaxis.
In terms of IFI prevention and overall survival, there were
no statistically signiﬁcant differences between voriconazole and
itraconazole. However, it should be noted that voriconazole
patients required signiﬁcantly fewer other licensed systemic
antifungal agents, including caspofungin and liposomal
amphotericin B. These ﬁndings are mirrored in a number of
other recently published azole prophylaxis trials in the same
setting. For instance, a randomized, double-blind study
comparing voriconazole with ﬂuconazole in standard-risk
alloHCT recipients [conducted by the Blood and Marrow
Transplant Clinical Trials Network (BMT-CTN)] was also
unable to show differences in IFI incidence or overall survival,
but similarly reported a lower use of empirical antifungal
therapy in voriconazole patients (Wingard et al, 2010). Of
note, another randomized trial, evaluating posaconazole
against ﬂuconazole in high-risk alloHCT recipients, also failed
to demonstrate a signiﬁcant difference in overall IFI incidence
or survival, but reported fewer cases of proven or probable IA
in the posaconazole arm (Ullmann et al, 2007). On the other
hand, in a small retrospective study conducted in a similar
population, voriconazole was more effective than ﬂuconazole/
itraconazole in preventing not just IA, but also IFIs overall
(Gergis et al, 2010). The lack of signiﬁcant differences in IFI
incidence or survival during previous prospective clinical trials
prompted us to choose a composite measure as the primary
endpoint in this study, in order to facilitate the detection of
relevant clinical differences between the two study drugs.
Similar composite endpoints may also be useful in future
comparative trials in antifungal prophylaxis.
Of note, the incidence of breakthrough IFIs in our trial was
unusually low compared with other published studies. One
possible explanation is that it was not always possible to
perform bronchoscopy or biopsy for the purpose of conﬁrm-
ing invasive fungal disease in this patient population. In
addition, routine galactomannan monitoring was not part of
our study design. In contrast, the BMT-CTN study did
incorporate intensive galactomannan monitoring, which facil-
itated the diagnosis of more than half of all probable IA cases
in that trial (Wingard, et al, 2010). However, the value of
routine galactomannan screening in a study comparing
mould-active agents for prophylaxis is debatable (Marr et al,
2005). We used the 2002 European Organization for Research
and Treatment of Cancer/Mycoses Study Group (EORTC/
MSG) deﬁnitions of proven or probable IFI in our study
(Ascioglu et al, 2002), but the utility of these deﬁnitions in the
context of antifungal prophylaxis trials has recently been
questioned (Wingard et al, 2010). For example, the BMT-CTN
study incorporated a new category of ‘presumptive IFI’
(Wingard et al, 2010). We are planning a future analysis of
breakthrough invasive fungal disease in our study, which will
include possible, in addition to probable and proven, IFIs
based on the latest EORTC/MSG deﬁnitions.
Our ﬁndings may also have been affected by the inclusion of
patients with reduced-intensity conditioning regimens, who
were excluded from previous studies of antifungal prophylaxis
after alloHCT. This population, which constitutes a major
proportion of patients in modern transplant practice, may
have a lower IFI risk particularly during the pre-engraftment
period, but a similar risk of IFI (i.e. mainly IA) after
engraftment (Martino et al, 2001, 2002).
Our study has some limitations. In theory, it would have
been preferable to employ a blinded study design. The lack of
blinding potentially affected investigator-assessed toxicities
and decisions regarding the use of other antifungal agents.
However, this approach would have required that voriconazole
patients take an oral cyclodextrin placebo. Not only would this
be unethical in patients who already have difﬁculties taking
oral drugs, but it would also have impaired our ability to
compare tolerability between the study agents.
Another limitation of the study is the lack of plasma drug
level data in many patients: documented steady-state trough
levels were available for only 15% of voriconazole and 10% of
itraconazole patients. Among these, 83% of itraconazole
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recommended as the minimal serum concentration for this
drug (Glasmacher et al, 2003). The target voriconazole con-
centration for prophylaxis is unknown; however, levels were
>0Æ5 lg/ml in 65% and >1Æ0 lg/ml in 38% of patients with
trough concentrations measured. There were insufﬁcient data
in this study to assess the relationship between voriconazole
concentrations and efﬁcacy or toxicity. Finally, it should be
pointed out that the intravenous formulation of itraconazole is
no longer commercially available; however, this should not be
an issue in terms of extending our results to clinical practice, as
few of our patients received intravenous itraconazole.
In conclusion, this study demonstrated that voriconazole
and itraconazole were equivalent in terms of survival and
prevention of IFI when used as antifungal prophylaxis after
alloHCT. However, patients were able to receive voriconazole
for signiﬁcantly longer durations, despite the fact that more
hepatic and visual toxicities were reported with this agent. In
addition, there was less need for other systemic antifungals
compared with itraconazole. In alloHCT recipients requiring a
mould-active, orally available agent for the prevention of IFI,
voriconazole may be a better option than itraconazole.
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